文献速递冠心病血脂与心血管预防

强效P2Y12抑制剂在男性与女性中的协作荟萃分析

Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

结果显示,强效P2Y12抑制剂在女性和男性中降低主要不良心血管事件(MACE)风险的程度相当(女性HR 0.86,男性HR 0.85,交互作用P=0.93),大出血风险在女性中未达统计学显著(HR 1.28,95%CI 0.87-1.88),在男性中显著增加(HR 1.52,95%CI 1.12-2.07),交互作用P=0.62。结论认为性别不应影响强效P2Y12抑制剂的患者选择。

要点

  • 强效P2Y12抑制剂降低MACE风险在女性(HR 0.86)与男性(HR 0.85)中相当,交互作用P=0.93。
  • stent血栓风险在女性降低51%(HR 0.49),男性降低41%(HR 0.59),交互作用P=0.85。
  • 大出血在女性未达统计学显著(HR 1.28,95%CI 0.87-1.88),男性显著增加(HR 1.52,95%CI 1.12-2.07)。

核心结论

  • 在随机试验中,强效P2Y12抑制剂的疗效和安全性在男性和女性之间相当。
  • 基于这些数据,性别不应影响强效P2Y12抑制剂给药的患者选择。

研究设计与样本

  • 试验涉及强效P2Y12抑制剂包括普拉格雷、替格瑞洛和静脉坎格瑞洛。
  • 主要终点为各试验定义的主要不良心血管事件(MACE)。

主要发现

  • 强效P2Y12抑制剂使女性MACE风险降低14%(HR 0.86,95%CI 0.78-0.94),男性降低15%(HR 0.85,95%CI 0.80-0.90),交互作用P=0.93。
  • 心肌梗死风险在女性降低13%(HR 0.87,95%CI 0.78-0.96),男性降低16%(HR 0.84,95%CI 0.77-0.91),交互作用P=0.65。
  • 支架血栓风险在女性降低51%(HR 0.49,95%CI 0.37-0.65),男性降低41%(HR 0.59,95%CI 0.42-0.84),交互作用P=0.85。
  • 心血管死亡在女性HR 0.87(95%CI 0.76-1.01),男性HR 0.85(95%CI 0.77-0.95),交互作用P=0.86。
  • 大出血在女性HR 1.28(95%CI 0.87-1.88),男性HR 1.52(95%CI 1.12-2.07),交互作用P=0.62。

临床怎么用

  • 作者认为,基于这些数据,性别不应影响强效P2Y12抑制剂给药的患者选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sex-specific differences in response to antiplatelet therapies have been described. Whether women and men derive comparable benefit from intensification of antiplatelet therapy remains uncertain. OBJECTIVES: The study investigated the efficacy and safety of the potent P2Y12 inhibitors in patients with coronary artery disease. METHODS: A collaborative sex-specific meta-analysis was conducted of phase III or IV randomized trials of potent P2Y12 inhibitors, including prasugrel, ticagrelor, and intravenous cangrelor. Seven trials were included that enrolled a total of 24,494 women and 63,346 men. Major adverse cardiovascular events (MACE) were defined as the primary endpoint for each trial. RESULTS: Potent P2Y12 inhibitors significantly reduced the risk of MACE by 14% in women (hazard ratio [HR]: 0.86; 95% confidence interval [CI]: 0.78 to 0.94) and by 15% in men (HR: 0.85; 95% CI: 0.80 to 0.90; p interaction = 0.93). Treatment reduced the risk of myocardial infarction by 13% in women (HR: 0.87; 95% CI: 0.78 to 0.96) and 16% in men (HR: 0.84; 95% CI: 0.77 to 0.91; p interaction = 0.65), and the risk of stent thrombosis by 51% in women (HR: 0.49; 95% CI: 0.37 to 0.65) and 41% in men (HR: 0.59; 95% CI: 0.42 to 0.84; p interaction = 0.85). Directional consistency was seen for cardiovascular death in women (HR: 0.87; 95% CI: 0.76 to 1.01) and men (HR: 0.85; 95% CI: 0.77 to 0.95; p interaction = 0.86). The potent P2Y12 inhibitors increased major bleeding in women (HR: 1.28; 95% CI: 0.87 to 1.88) and men (HR: 1.52; 95% CI: 1.12 to 2.07; p interaction = 0.62). CONCLUSIONS: In randomized trials, the efficacy and safety of the potent P2Y12 inhibitors were comparable between men and women. Given these data, sex should not influence patient selection for the administration of potent P2Y12 inhibitors.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lau ES, Braunwald E, Murphy SA, et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017. PMID: 28335837. doi:10.1016/j.jacc.2017.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。